Autoimmune biotech Kiniksa prices upsized $152M IPO as Scholar Rock bags $75M for preclinical SMA drug
Two biotechs that have been on parallel IPO tracks are blasting off with sizable support for their Nasdaq debuts.
Kiniksa got the bulkier raise among …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
